Estrategias Combinadas en Inmunoterapia Traslacional
ITC
Hospital Universitario Virgen del Rocío
Sevilla, EspañaPublicacións en colaboración con investigadores/as de Hospital Universitario Virgen del Rocío (13)
2024
2022
-
Integrating digital pathology with transcriptomic and epigenomic tools for predicting metastatic uterine tumor aggressiveness
Frontiers in Cell and Developmental Biology, Vol. 10
-
Molecular Biomarkers of Prognosis in Advanced Renal Cell Carcinoma Patients Treated With Pazopanib Plus Interferon Alpha (INF-2A) in a Phase I/II Study by the Spanish Oncology Genitourinary Group
Clinical Genitourinary Cancer, Vol. 20, Núm. 4, pp. 388.e1-388.e10
2021
-
Characterizing the Invasive Tumor Front of Aggressive Uterine Adenocarcinoma and Leiomyosarcoma
Frontiers in Cell and Developmental Biology, Vol. 9
-
Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-treated Patients with Advanced Urinary Tract Carcinoma
European Urology Focus, Vol. 7, Núm. 5, pp. 1084-1091
2020
-
Final Overall Survival Analysis of the SOGUG Phase 2 MAJA Study: Maintenance Vinflunine Versus Best Supportive Care After First-Line Chemotherapy in Advanced Urothelial Carcinoma
Clinical Genitourinary Cancer, Vol. 18, Núm. 6, pp. 452-460
2018
-
Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens
European Urology, Vol. 73, Núm. 3, pp. 462-468
-
Radium-223 international early access program: Results from the Spanish subset
Future Oncology, Vol. 14, Núm. 1, pp. 41-50
2017
-
HIF pathway and c-Myc as biomarkers for response to sunitinib in metastatic clear-cell renal cell carcinoma
OncoTargets and Therapy, Vol. 10, pp. 4635-4643
-
Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial
The Lancet Oncology, Vol. 18, Núm. 5, pp. 672-681
2014
-
Cost analysis of skeletal-related events in Spanish patients with bone metastases from solid tumours
Clinical and Translational Oncology, Vol. 16, Núm. 3, pp. 322-329
2009
-
Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-α as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population
Annals of Oncology, Vol. 20, Núm. 11, pp. 1803-1812